Homozygous deletion ofCDKN2B, encoding p15INK4b, has been described in 47% of all glioblastoma patients.119Interestingly,CDKN2Bmutations were associated with a significantly increased risk of cancer-associated thrombosis in patients with solid tumors, independent of cancer type.122In the same study,CDKN2Awas also part of the top 10 of somatic mutations that associate with an increased VTE risk in cancer patients, although significance was lost after false discovery rate adjustment. Here, CDKN2B is linked to cancer.